BLAINTRAVENOUS, SUBCUTANEOUSINJECTABLE3 Generics Approved
Approved
Oct 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ACTEMRA (tocilizumab) by Roche is interleukin 6 receptor antagonists [moa]. Approved for interleukin-6 receptor antagonist [epc]. First approved in 2013.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTEMRA (tocilizumab) is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, reducing inflammatory cytokine signaling. It is indicated for rheumatoid arthritis and other inflammatory conditions, administered via intravenous or subcutaneous injection. The drug works by inhibiting IL-6 receptor-mediated inflammation, a key driver of joint damage and systemic inflammation.
Peak
ACTEMRA is a mature, peak-lifecycle product with established market presence; commercial teams focus on maintaining market share and defending against biosimilar/generic competition rather than rapid expansion.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Started Jul 2026
30 enrolled
Relapsed/Refractory Multiple Myeloma (RRMM)
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Started Jun 2026
230 enrolled
Multiple Myeloma
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Started Jan 2026
78 enrolled
Giant Cell Arteritis (GCA)
RCT of Tocilizumab for Anti-MDA5+DM
Started Nov 2025
110 enrolled
Dermatomyositis
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
Started Oct 2025
60 enrolled
Acute Hypoxemic Respiratory Failure
Worked on ACTEMRA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.